GlassScriptPhysician profile
Alina Goldenberg
NPI 1710374889
$11,185.76
in general payments reported to CMS, 2019-2025
29 companies · $2,210 in 2025
The $2,210 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $263 · 2021: $1,428 · 2022: $895 · 2023: $3,163 · 2024: $2,491 · 2025: $2,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,452 · Consulting Fee: $1,180 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,452.11 |
| Consulting Fee | $1,180.00 |
| Education | $231.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,186.48 | 2019-2025 | |
| Ucb, INC. | $1,370.59 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $760.78 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $747.24 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $660.29 | 2019-2025 | Sotyktu |
| Genzyme Corporation | $655.96 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $613.71 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $596.05 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $539.22 | 2021-2025 | Ilumya, Winlevi |
| Regeneron Healthcare Solutions, INC. | $443.99 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $441.96 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $343.74 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $278.78 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $276.12 | 2021-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $254.09 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $227.28 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.01 | 2023-2025 | Spevigo |
| Regeneron Pharmaceuticals, INC. | $108.96 | 2023 | Libtayo |
| Dermavant Sciences, INC. | $99.63 | 2023-2024 | Vtama |
| Allergan, INC. | $97.33 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.39 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $68.81 | 2021 | |
| Almirall LLC | $34.95 | 2021-2023 | Klisyri |
| Organon LLC | $28.40 | 2025 | Vtama |
| Biofrontera INC. | $26.08 | 2021-2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Celgene Corporation | $24.34 | 2019 | |
| Vyne Pharmaceuticals INC. | $21.71 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $19.98 | 2022 | |
| Merck Sharp & Dohme LLC | $18.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alina Goldenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.